Can neurofilament light chain predict neurotoxicity after CAR-T cell therapy?

Researchers in Seattle have assessed whether neurofilament light chain (NfL) predicts neurotoxicity after treatment with chimeric antigen receptor (CAR) T cell therapy.

Neurotoxicity is a common complication of cancer immunotherapy, according to Dr Juliane Gust of Seattle Children’s Hospital in Washington, USA. “For CAR-T cells, which are modified patient T cells that are redirected to attack cancer cells, we see neurotoxicity in about 40% of patients,” she said. Possible manifestations include altered mental status, seizure, coma, and cerebral edema.

Dr Gust and colleagues measured NfL levels in a series of children with relapsed/refractory lymphoma undergoing CAR-T cell therapy. Samples of serum and cerebrospinal fluid (CSF) were collected before and 7–10 days after treatment.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.